Related Experiment Video
Updated: Feb 11, 2026
12:03
Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma
Published on: July 25, 2011
20.0K
β-Adrenergic Signaling Promotes Anti-Tumor Immunity in TP53-mutant Oral Squamous Cell Carcinoma
Frederico O Gleber-Netto1, Deborah Silverman1, Tongxin Xie1
1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|February 10, 2026
Summary
Stimulating beta-adrenergic receptors enhances T cell activity against head and neck cancer lacking p53. This neuro-immune axis uses CXCL10 to recruit T cells, potentially overcoming immunotherapy resistance in p53-deficient tumors.
Area of Science:
- Immunology
- Neuroscience
- Oncology
Background:
- Head and neck squamous cell carcinoma (HNSCC) exhibits resistance to immunotherapy.
- The roles of beta-adrenergic signaling and p53 loss in tumor-immune evasion are not well understood.
Purpose of the Study:
- To investigate the interplay between beta-adrenergic signaling, p53 status, and immune evasion in HNSCC.
- To explore the potential of targeting the neuro-immune axis to enhance immunotherapy.
Main Methods:
- Pharmacologic stimulation of beta2-adrenergic receptors using isoprenaline.
- Transcriptomic analysis and co-culture assays with HNSCC cells.
- In vivo studies using tyrosine hydroxylase knockout mouse models.
- CXCL10 neutralization and T cell marker analysis.
Main Results:
- Isoprenaline enhances cytotoxic T cell activity against p53-deficient HNSCC cells via CXCL10.
- p53-null HNSCC cells upregulate CXCL10, promoting CD8+ T cell recruitment and activation.
- Adrenergic innervation is crucial for intra-tumoral CXCL10 and T cell infiltration in vivo.
- The T cell response shows both activation and exhaustion markers.
Conclusions:
- A neuro-immune axis involving beta-adrenergic signaling and CXCL10 reverses immune escape in p53-deficient HNSCC.
- Targeting adrenergic signaling may convert "cold" tumors to "hot" ones, improving immunotherapy response.
Related Concept Videos
01:26Adrenergic Receptors: β Subtype
3.9K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.9K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.0K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.0K
01:16TGF - β Signaling Pathway
10.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.6K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.5K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.5K